Saline-filled breast implants contain a silicone outer shell filled with a sterile saltwater (saline) solution. Some are pre-filled and others are filled during the implant operation. Saline-filled implants come in different sizes and have either smooth or textured shells. The FDA approved saline-filled breast implants for breast augmentation in women age 18 or older and for breast reconstruction in women of any age. They are also used in revision surgeries, which correct or improve the result of an original surgery.
There are a few alternatives to breast augmentation with implants. Fat grafting breast augmentation involves harvesting fat via liposuction from another area of your body and injecting it into your breasts. Fat grafting is typically used to improve the appearance of your breasts after surgery to treat breast cancer, to correct a congenital breast deformity or to even out any imperfections occurring after breast augmentation with implants, such as wrinkles or ripples. The long-term effects of fat grafting to a normal breast are not fully understood, and the degree of augmentation possible via grafting is only modest at best. For these reasons, fat grafting for cosmetic breast augmentation is still considered experimental by many plastic surgeons.
Transaxillary: an incision made to the axilla (armpit), from which the dissection tunnels medially, to emplace the implants, either bluntly or with an endoscope (illuminated video microcamera), without producing visible scars on the breast proper; yet, it is likelier to produce inferior asymmetry of the implant-device position. Therefore, surgical revision of transaxillary emplaced breast implants usually requires either an IMF incision or a periareolar incision.
Both breast reduction and breast lift surgeries are similar in that they both serve to reshape the breasts. Breast lift, through any of the various techniques, basically serves to reposition the breast and nipple on the chest to reverse the effects of time and gravity. The same changes that are noted in ptotic, or sagging, breasts are often seen in large breasts that require reduction: the nipple position is often low and there is excess skin (in addition to the excess breast tissue). The breast reduction then combines a lift with removal of extra tissue to create a breast that has a higher nipple position, reduced extra skin, and smaller and more balanced breast size.
I love so many of my features. For instance, the green eyes I got from my mom, my naturally full lips, and smile, but my nose has been a source of insecurity. Around 15, as puberty hit, my nose just...changed. One day, it suddenly looked large and awkward, with a pronounced bump and protruding tip that I simply didn't identify with. I'd catch my profile in the mirror and be uncomfortable with the face staring back.
When talking about the price with your plastic surgeon, it’s important to know exactly what the cost covers. Is it just the surgeon’s fee? Or will it cover anesthesia, facility fees, implant cost, medical tests, pre- or post-op appointments, and medical supplies you’ll need during recovery? Do you need to purchase a specific bra for recovery or will they provide one?
Unfortunately, as time goes on it is often difficult for patients to remember the specifics of the type of breast augmentation surgery and implants that they had. Your are not alone! The easiest way to determine what type of implant you had is to request a copy of the operative report from either the hospital, surgery center or your surgeon's office. The implant specifics are recorded on this document. Your office record also includes this information. If it has been over ten years since your procedure, sometimes these records are no longer available. Ultrasound or MRI can help to answer this question but it is an expensive way to solve the mystery and not an indication for these procedures. If you registered your implants with the manufacturer at the time of surgery, the company will have a record of this information. Fortunately, this inforation is not absoltely critical to your health unless you are having a problem with your implants. Your surgeon can often develop a reasonable treatment plan even without this information. I would strongly recommend that you register your implants and purchase the affordable insurance program if you have surgery again. These programs are helpful in storing vital information regarding your implant type, size, filler, model and lot number. Should there be a recall or long term problem requiring additional surgery, this information is readily available. There is often also some fiancial support to offset costs. Investigate the options available by contacting your surgeon or the implant manufacturer's websites.
After reviewing the medical data, the U.S. Food and Drug Administration concluded that TDA-induced breast cancer was an infinitesimal health-risk to women with breast implants, and did not justify legally requiring physicians to explain the matter to their patients. In the event, polyurethane-coated breast implants remain in plastic surgery practice in Europe and in South America; and no manufacturer has sought FDA approval for medical sales of such breast implants in the U.S.
In 1988, twenty-six years after the 1962 introduction of breast implants filled with silicone gel, the U.S. Food and Drug Administration (FDA) investigated breast implant failures and the subsequent complications, and re-classified breast implant devices as Class III medical devices, and required from manufacturers the documentary data substantiating the safety and efficacy of their breast implant devices. In 1992, the FDA placed silicone-gel breast implants in moratorium in the U.S., because there was “inadequate information to demonstrate that breast implants were safe and effective”. Nonetheless, medical access to silicone-gel breast implant devices continued for clinical studies of post-mastectomy breast reconstruction, the correction of congenital deformities, and the replacement of ruptured silicone-gel implants. The FDA required from the manufacturers the clinical trial data, and permitted their providing breast implants to the breast augmentation patients for the statistical studies required by the U.S. Food and Drug Administration. In mid–1992, the FDA approved an adjunct study protocol for silicone-gel filled implants for breast reconstruction patients, and for revision-surgery patients. Also in 1992, the Dow Corning Corporation, a silicone products and breast implant manufacturer, announced the discontinuation of five implant-grade silicones, but would continue producing 45 other, medical-grade, silicone materials—three years later, in 1995, the Dow Corning Corporation went bankrupt when it faced large class action lawsuits claiming a variety of illnesses.
The FDA has identified that breast implants may be associated with a rare form of cancer called anaplastic large-cell lymphoma, believed to be associated with chronic bacterial inflammation. Similar ALCL phenomena have been seen with other types of medical implants including vascular access ports, orthopedic hip implants, and jaw (TMJ) implants. As of February 1, 2017, the FDA has received a total of 359 medical device reports of breast-implant-associated ALCL (BIALCL), including 9 deaths. Most cases of breast implant-associated ALCL had implants in for many years prior to the condition, and are usually treated successfully by simple removal of the implant and the capsule surrounding the implant without the need for chemotherapy if no evidence of systemic disease exists. If women with implants present with delayed swelling or fluid collection, cytologic studies and test for a marker "CD30" are suggested. The American Society of Plastic Surgery (ASPS) states, "CD30 is the main diagnostic test that must be performed on the seroma fluid as routine pathology or H&E staining can frequently miss the diagnosis."  Diagnosis and treatment of breast implant associated ALCL now follows standardized guidelines established by the National Comprehensive Cancer Network.